Outcome of the Meeting of the Board of Directors of the Company held on May 21, 2026, is attached.
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.9 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Agarwal's Health Care Limited reported strong FY2026 results with total income of ₹2,125 crores, up 20.9% YoY. Revenue from operations grew 21.6% to ₹2,080 crores, crossing the ₹2,000 crore milestone for the first time. EBITDA increased 22.2% to ₹614 crores with margins expanding to 28.9% from 28.6% in FY2025. PAT surged 52.4% to ₹168 crores, significantly outpacing revenue growth due to operating leverage. The company added 57 new facilities during the year, taking the total network to 288 across 10 countries. Q4 FY2026 showed revenue of ₹564 crores (up 22.6% YoY), EBITDA of ₹174 crores with 30.2% margins, and PAT of ₹50 crores. The Board also approved reallocation of ₹14.88 crore unspent IPO proceeds from Issue Related Expenses to General Corporate Purposes and Unidentified Inorganic Acquisitions, citing effective cost management during the IPO.
Strong all-round growth with PAT outpacing revenue growth signals improving operational efficiency. EBITDA margin expansion to 28.9% demonstrates better cost management and scalability. The stock appears positioned well with 52% PAT growth and expanding margins.